Lilly Collaborates with Kumquat to Develop Novel Little Particles that Boost Tumor-Specific Immune Responses
Kumquat to get an ~ $70M in upfront and an equity investment in addition to ~$ 2B in turning point based upon the achievement of definite milestones in addition to royalties on sales of commercialized products resulting from the cooperation
Following the contract, Lilly gets the option to co-commercialize in China while Kumquat has the option to co-commercialize and co-develop in the US
Kumquat holds the advancement and commercialization rights in Greater China for each drug candidate that Lilly selects while Lilly has the option to choose a guaranteed variety of drug candidates for further advancement and commercialization worldwide Ex- Greater China
Click on this link to read full news release/ short article|Ref: Eli Lilly|Image: Kumquat.